Exclusion Criteria:~* Patients who discontinued treatment permanently in Study BN29552 or BN29553 for safety
reasons.~* Impaired coagulation.~* Evidence of more than 10 microbleeds and/or ARIA-H (amyloid-related imaging
abnormalities-hemosiderin deposition) at the Study BN29552 or BN29553 Week 105 visit, as assessed by central
review of MRI.~* Diagnosed with three recurrent, symptomatic ARIA-E (amyloid-related imaging
abnormalities-edema/effusion) events or exacerbations of previous events.~* Presence of intracranial lesion
that could potentially increase the risk of CNS (Central Nervous System) bleeding.~* At risk of suicide in the
opinion of the investigator.~* Alcohol and/or substance abuse or dependence within the past 2 years and during
the study.~* Inability to tolerate MRI procedures or contraindication to MRI, including, but not limited to,
presence of pacemakers not compatible with MRI, aneurysm clips, artificial heart valves, ear implants, or
foreign metal objects in the eyes, skin, or body that would contraindicate an MRI scan; or any other clinical
history or examination finding that, in the judgment of the investigator, would pose a potential hazard in
combination with MRI.~* Pregnant or lactating, or intending to become pregnant during the study.~* Any other
severe or unstable medical condition that, in the opinion of the investigator or Sponsor, could be expected to
progress, recur, or change to such an extent that it could put the patient at special risk, bias the assessment
of the clinical or mental status of the patient to a significant degree, or interfere with the patient's
ability to complete the study assessments.~* Chronic use of anticoagulants or participation in any other
investigational drug treatment trial.
